U045 Combining Systemic Therapies: Should You Do It?
DESCRIPTION
With the expansion of our treatment armamentaria in dermatology we have many tools in our toolbox to manage treatment failure and patients with multiple dermatologic conditions. Practicing dermatologists are now getting introduced to all these new therapies including JAK inhibitors and emerging biologics. The use of these new agents in combination with each other or with more traditional immunomodulators are not well established. This session is targeted to familiarize practicing dermatologists on how to combine these medications in our daily practice and how to assess their safety profile in this setting.
LEARNING OBJECTIVES
Select the appropriate biologic and immunomodulator combinations in the real world.
Manage treatment failure with combination therapy.
Assess the safety profile of combining multiple agents.
SCHEDULE
4:30 PM
Combining Systemic Therapies: Connective tissue diseases
Carole Bitar, MD, FAAD
4:45 PM
Combining Systemic Therapies: Psoriasis
Erin E. Boh, MD, PhD, FAAD
4:55 PM
Combining Systemic Therapies: Hidradenitis Suppurativa
Andrea Tesvich Murina, MD, FAAD
5:05 PM
Combining Systemic Therapies: Immunobullous diseases
Katherine Brag, MD, FAAD
5:15 PM
Q&A
DIRECTOR
Carole Bitar, MD, FAAD
SPEAKERS
Erin E. Boh, MD, PhD, FAAD
Katherine Brag, MD, FAAD
Andrea Tesvich Murina, MD, FAAD
HANDOUTS
DISCLOSURES
Carole Bitar, MD, FAAD
No financial relationships exist with ineligible companies.
Erin E. Boh, MD, PhD, FAAD
AbbVie – Investigator(Grants/Research Funding), Speaker(Honoraria); Arcutis Biotherapeutics – Advisory Board(Honoraria); BMS – Speaker(Honoraria); Boehringer Ingelheim – Speaker(Honoraria); Castle Biosciences – Investigator(Grants/Research Funding); Dermavant Sciences – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Dermira/Lilly – Investigator(Grants/Research Funding); Incyte Corporation – Investigator(Grants/Research Funding), Speaker(Honoraria); Janssen-Ortho Inc. – Investigator(Grants/Research Funding), Speaker(Honoraria); Ortho Dermatologics – Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding);
Katherine Brag, MD, FAAD
No financial relationships exist with ineligible companies.
Andrea Tesvich Murina, MD, FAAD
AbbVie – Speaker(Honoraria); Amgen – Speaker(Honoraria); Boehringer Ingelheim – Consultant (1099 relationship)(Honoraria); Botanix Pharmaceuticals – Speaker(Honoraria); Bristol-Myers Squibb – Speaker(Honoraria); Eli Lilly and Company – Speaker(Honoraria); Galderma – Speaker(Honoraria); Janssen Biotech – Speaker(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria); Ortho Dermatologics – Advisory Board(Honoraria), Speaker(Honoraria); Pfizer Inc. – Speaker(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); UCB – Advisory Board(Honoraria); UCB Pharma – Speaker(Honoraria);